The Asthma and COPD Market Outlook: Market analysis of future growth and leading players by sector

Business Insights have teamed up with IMS Health to bring you, ‘The Asthma and COPD Market Outlook: Market analysis of future growth and leading players by sector.’ This unique product offering provides an analysis of changing market conditions and strategic future outlook using the gold standard IMS Health sales data and Business Insights ’ expert analysis, an unrivalled source of pharmaceutical intelligence on the asthma and COPD market. Refresh your asthma strategy with new analysis In terms of revenue, the asthma and COPD therapeutic area historically ranks as the sixth largest single source of sales for the pharmaceutical industry. The outlook for the market is currently strong, driven by strategically sound lifecycle management from the major players in the asthma and COPD area, new product launches and favourable epidemiology. Generic competition will continue to remain the major threat to sales growth in this market. The Asthma and COPD Market Outlook: Market analysis of future growth and leading players by sector, provides detailed analysis of all classes of asthma and chronic obstructive pulmonary disease (COPD) drugs across all major indications. Forecasts are provided over the period 2004-2009,enabling you to identify the market leaders of the future and spot potential opportunities and threats to your market position.
[Studien Infos ausblenden]

The Asthma and COPD Market Outlook: Market analysis of future growth and leading players by sector
Executive summary
Epidemiology analysis
Global asthma/COPD market analysis
First/second-line treatment market analysis
Third-line asthma treatments market analysis
Leading players in the asthma/COPD market

Chapter 1 Epidemiology analysis

Summary
Introduction
Disease description
Asthma
Chronic Obstructive Pulmonary Disease
Disease classification
Asthma
COPD
Current and future prevalence of asthma/COPD
Asthma
COPD
Diagnosis
Asthma
COPD
Current and future treatment patterns

Chapter 2 Global asthma/COPD market analysis

Summary
Introduction
History of asthma drugs
Current growth drivers
SABA/LABA treatments
ICS
Xanthines
Oral corticosteroids
Combination therapies
Anticholinergics and leukotriene antagonists
Future growth drivers
Monoclonal antibodies
Anti-muscarinics

Chapter 3 First and second-line therapies: Beta-2 agonists, ICS and combination ICS/LABA drugs

Summary
Introduction
First and second-line treatment categories and sales
Company market share
Brand market share and sales
SABA/LABA treatments
Brand analysis
Serevent (salmeterol xinfoate)
Xopenex (levalbuterol)
Ventolin (salbutamol/albuterol)
Foradil (formoterol fumarate)
ICS treatments
Brand analysis
Flixotide/Flovent (fluticasone propionate)
Pulmicort (budesonide)
LABA/ICS combination treatments
Brand analysis
Seretide/Advair (fluticasone propionate and salmeterol xinfoate)
Symbicort (budesonide and formoterol)

Chapter 4 Third-line therapies and beyond: leukotriene antagonists, anticholinergics and other drugs

Summary
Introduction
Third-line treatment categories and sales
Company market share
Brand market share and sales
Leukotriene antagonist treatments
Brand analysis
Singulair (montelukast)
Anticholinergic and SABA/anticholinergic treatments
Brand analysis
Combivent (ipratropium and salbutamol)
Atrovent (ipratropium)
Spiriva (tiotropium)

Chapter 5 Leading players in the asthma/COPD market

Summary
Introduction
Merck & Co
Therapeutic focus
Third-line treatment market share
Marketed products
R&D pipeline
GSK
Therapeutic focus
First and second-line treatment market shares
Marketed products
R&D pipeline
Ariflo
Boehringer Ingelheim
Therapeutic focus
Anticholinergic market share
Marketed products
Schering-Plough
Therapeutic focus
Marketed products
R&D pipeline
AstraZeneca
Therapeutic focus
Marketed products
R&D pipeline
Novartis
Therapeutic focus
Marketed products
R&D pipeline
Xolair (omalizumab)
QAB149
Sepracor
Therapeutic focus
Marketed products
R&D pipeline
Alformoterol
Altana
Therapeutic focus
Marketed products
R&D pipeline
Alvesco (ciclesonide)
Daxas (roflumilast)
Index
[Inhaltsverzeichnis ausblenden]

Table 1.1: Classification of asthma sufferers according to disease severity 19
Table 1.2: Estimated prevalence of asthma in children and adults across the US & 5 European markets, 2003 21
Table 1.3: Estimated prevalence of asthma in the US & 5 major European markets, 2003-201323
Table 1.4: Estimated prevalence of adult COPD in the US & 5 major European markets, 2003- 2013 26
Table 1.5: Estimates of the number and proportion of patients receiving asthma treatments by drug class, 2003 31
Table 1.6: US and European* Sales by Drug Class ($m), 2002-2003 32
Table 2.7: US/European* sales category totals ($m), 2002-2003 36
Table 3.8: US/European* Sales of first and second-line asthma/COPD treatments by category ($m), 2002-2003 44
Table 3.9: First/second-line therapy market share by company and territory (%), 2002-2003 45
Table 3.10: Sales of leading 1st/2nd-line treatments by country ($m), 2002-03 50
Table 3.11: Branded SABA/LABA treatments 51
Table 3.12: Branded ICS treatments 57
Table 3.13: Branded LABA/ICS combination treatments 61
Table 4.14: US/European* Sales of third-line asthma/COPD treatments by category ($m), 2002- 2003 68
Table 4.15: Third-line therapy market share by company and territory (%), 2002-2003 69
Table 4.16: Sales of major branded third-line treatments by country, 2002-03 73
Table 4.17: Major branded leukotriene antagonist treatments 75
Table 4.18: Branded ACh and SABA/ACh treatments 77
Table 5.19: US/European* asthma/COPD market share by company (%), 2002-03 85
Table 5.20: US/European* leukotriene antagonist market share by company (%), 2002-03 87
Table 5.21: US/European* sales of Merck & Co’s marketed asthma/COPD portfolio ($m), 2002- 2003 88
Table 5.22: Projected sales of Merck’s asthma/COPD R&D pipeline ($m), 2007 & 2010 88
Table 5.23: US/European* first/second-line treatment market share by company (%), 2002-200390
Table 5.24: US/European* sales of GSK’s marketed asthma/COPD portfolio ($m), 2002-2003 90
Table 5.25: Projected sales of GSK’s asthma/COPD R&D pipeline ($m), 2007 & 2010 91
Table 5.26: US/European* anticholinergic treatment market share by company (%), 2002-2003 94
Table 5.27: US/European* sales of Boehringer Ingelheim’s marketed asthma/COPD portfolio ($m), 2002-2003 94
Table 5.28: US/European* sales of Schering-Plough’s marketed asthma/COPD portfolio ($m), 2002-2003 96
Table 5.29: Projected sales of Schering-Plough’s asthma/COPD R&D pipeline ($m), 2007 & 2010 96
Table 5.30: US/European* sales of AstraZeneca’s marketed asthma/COPD portfolio ($m), 2002- 2003 98
Table 5.31: Projected sales of AstraZeneca’s asthma/COPD R&D pipeline ($m), 2007 & 2010 98
Table 5.32: US/European* sales of Novartis’ marketed asthma/COPD portfolio ($m), 2002-2003 100
Table 5.33: Projected sales of Novartis’ asthma/COPD R&D pipeline ($m), 2007 & 2010 100
Table 5.34: US/European* sales of Sepracor’s marketed asthma/COPD portfolio ($m), 2002-2003 102
Table 5.35: Projected sales of Sepracor’s asthma/COPD R&D pipeline ($m), 2007 & 2010 103
Table 5.36: Projected sales of Altana’s asthma/COPD R&D pipeline ($m), 2007 & 2010 105
Figure 1.1: Estimated relative prevalence of asthma patients by severity, 2003 19
Figure 1.2: Estimated variation in the prevalence of asthma in the US & five major European markets, 2003 21
Figure 1.3: Estimated prevalence of asthma in the US & 5 major European markets, 2003-201322
Figure 1.4: Estimated variation in the prevalence of COPD in the US & 5 major European markets, 2003 24
Figure 1.5: Estimated prevalence of COPD in the US & 5 major European markets, 2003-2013 25
Figure 1.6: Estimated proportion of patients presenting with asthma that are correctly diagnosed by visit 27
Figure 1.7: Typical treatment patterns in the treatment of asthma 29
Figure 1.8: Estimated proportion of patients on leading therapeutic classes of drugs used in the treatment of asthma by disease severity, 2003 30
Figure 2.9: Development timeline for major asthma/COPD drugs and classes 35
Figure 3.10: Asthma/COPD first/second-line brands by company and type, 2004 46
Figure 3.11: US/European* market share of leading inhaled corticosteroid brands (%), 1999-2003 47
Figure 3.12: US/European* market share of leading inhaled beta-2 agonist brands (%), 1999-2003 48
Figure 3.13: US/European* market share of leading inhaled beta-2 agonist brands (%), 1999-2003 49
Figure 3.14: Serevent SWOT analysis 52
Figure 3.15: Xopenex SWOT analysis 54
Figure 3.16: Ventolin SWOT analysis 55
Figure 3.17: Foradil SWOT analysis 56
Figure 3.18: Flixotide/Flovent SWOT analysis 59
Figure 3.19: Pulmicort SWOT analysis 60
Figure 3.20: Seretide/Advair SWOT analysis 62
Figure 3.21: Symbicort SWOT analysis 64
Figure 4.22: Asthma/COPD third-line brands by company and type, 2004 70
Figure 4.23: US/European* market share of leading leukotriene antagonist brands (%), 1999-2003 71
Figure 4.24: US/European* market share of leading anticholinergic and SABA/anticholinergic combination products (%), 1999-2003 72
Figure 4.25: Singulair SWOT analysis 76
Figure 4.26: Combivent SWOT analysis 78
Figure 4.27: Atrovent SWOT analysis 79
Figure 4.28: Spiriva SWOT analysis 80
Figure 5.29: Merck’s forecast therapeutic focus, 2003-2010 86
Figure 5.30: GSK’s therapeutic focus, 2003-2010 89
Figure 5.31: Boehringer Ingelheim’s therapeutic focus, 2003 & 2010 93
Figure 5.32: Schering-Plough’s forecast therapeutic focus, 2003-10 95
Figure 5.33: AstraZeneca’s forecast therapeutic focus, 2003-10 97
Figure 5.34: Novartis’ forecast therapeutic focus, 2003-10 99
Figure 5.35: Altana’s forecast therapeutic focus, 2003-10 104
[Tabellenverzeichnis ausblenden]